{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:32:51Z","timestamp":1788449571207,"version":"build-2803163510"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The follow-up strategy for unresected non-functional adrenal tumors (NFAT) is a major controversial issue in endocrinological clinical practice, as the natural history of adrenal incidentalomas (AI) is partially unknown and a consensus on their adequate management is lacking. In a recent longitudinal study by Ceccato et\u00a0al., a large cohort of patients with conservatively treated AI were evaluated for possible radiological variations over time and their relationship with autonomous cortisol secretion (ACS). Starting from this paper, we performed a literature review of available longitudinal studies focus on the same issue. Notwithstanding the high variability in the duration of follow-up and in the criteria used to define ACS in the included studies, our findings support the idea that there is a not negligible risk of morphological and functional changes, which may have metabolic implications, especially after 5-10 years of follow-up. Unfortunately, these variations seem to be scarcely predictable. Therefore, it may be risky to interrupt the follow-up in patients with NFAT, in particular in the presence of larger diameter of the adenoma and higher cortisol levels at diagnosis. These results should be considered in defining the optimal management of these patients.<\/jats:p>","DOI":"10.3389\/fendo.2023.1179817","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T14:06:46Z","timestamp":1686060406000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Predicting morphological and functional variations of benign adrenal incidentalomas in relation to initial characteristics"],"prefix":"10.3389","volume":"14","author":[{"given":"Chiara","family":"Parazzoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Favero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Aresta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"B1","author":"Fassnacht","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S2213-8587(20)30314-4","article-title":"Epidemiology of adrenal tumours in Olmsted county, Minnesota, USA: a population-based cohort study","volume":"8","author":"Ebbehoj","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.07.2799","article-title":"The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy","volume":"190","author":"Song","year":"2008","journal-title":"AJR Am J Roentgenol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/CLINEM\/DGZ284","article-title":"Adrenal incidentalomas are tied to increased risk of diabetes: findings from a prospective study","volume":"105","author":"Reimondo","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/JCEM.85.2.6372","article-title":"Angeli a. A Survey Adrenal Incidentaloma Italy","volume":"85","author":"Mantero","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7326\/M22-1619","article-title":"Prevalence and characteristics of adrenal tumors in an unselected screening population a cross-sectional study","volume":"175","author":"Jing","year":"2022","journal-title":"Ann Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3630","article-title":"Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess a systematic review and meta-analysis","volume":"171","author":"Elhassan","year":"2019","journal-title":"Ann Intern Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4158\/EP.15.5.450","article-title":"American Association of clinical endocrinologists and American association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas: executive summary of recommendations","volume":"15","author":"Zeiger","year":"2009","journal-title":"Endocr Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-5-200303040-00013","article-title":"Management of the clinically inapparent adrenal mass (\u201cincidentaloma\u201d)","volume":"138","author":"Grumbach","year":"2003","journal-title":"Ann Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/J.ANDO.2008.09.003","article-title":"Exploration and management of adrenal incidentalomas.: French society of endocrinology consensus","volume":"69","author":"Tabarin","year":"2008","journal-title":"Ann Endocrinol (Paris)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5603\/EP.A2016.0039","article-title":"Adrenal incidentaloma in adults - management recommendations by the polish society of endocrinology","volume":"67","author":"Bednarczuk","year":"2016","journal-title":"Endokrynol Pol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.794197","article-title":"Attenuation value in adrenal incidentalomas: a longitudinal study","volume":"12","author":"Ceccato","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/JCEM.84.2.5444","article-title":"Risk factors and long-term follow-up of adrenal incidentalomas","volume":"84","author":"Barzon","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-009-9260-5","article-title":"Adrenal incidentaloma, clinical, metabolic, follow-up aspects: single centre experience","volume":"37","author":"Comlekci","year":"2010","journal-title":"Endocrine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1470489","article-title":"Long-term follow-up study of patients with adrenal incidentalomas","volume":"147","author":"Lib\u00e8","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/SJ.BJC.6602459","article-title":"Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas","volume":"92","author":"Bernini","year":"2005","journal-title":"Br J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0299","article-title":"Usefulness of adrenal scintigraphy in the follow-up of adrenocortical incidentalomas: a prospective multicenter study","volume":"160","author":"Fagour","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2013.28.5.557","article-title":"Clinical characteristics and follow-up of Korean patients with adrenal incidentalomas","volume":"28","author":"Cho","year":"2013","journal-title":"Korean J Internal Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0372","article-title":"Optimal follow-up strategies for adrenal incidentalomas: reappraisal of the 2016 ESE-ENSAT guidelines in real clinical practice","volume":"177","author":"Hong","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13294","article-title":"Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged follow-up","volume":"86","author":"Papanastasiou","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2020-0182","article-title":"Nonfunctioning adrenal incidentalomas are not clinically silent: a longitudinal cohort study","volume":"26","author":"Kim","year":"2020","journal-title":"Endocrine Pract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1055\/a-1079-4915","article-title":"Clinical characteristics and follow-up results of adrenal incidentaloma","volume":"129","author":"Yilmaz","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0196","article-title":"Natural history of nonfunctioning adrenal incidentalomas: a 10-year longitudinal follow-up study","volume":"10","author":"Podbregar","year":"2021","journal-title":"Endocr Connect"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01539-y","article-title":"Maximum adenoma diameter, regardless of uni- or bilaterality, is a risk factor for autonomous cortisol secretion in adrenal incidentalomas","volume":"44","author":"Araujo-Castro","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02476-1","article-title":"Clinical features, risk of mass enlargement, and development of endocrine hyperfunction in patients with adrenal incidentalomas: a long-term follow-up study","volume":"71","author":"Falcetta","year":"2021","journal-title":"Endocrine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7326\/M21-1737","article-title":"Cardiometabolic disease burden and steroid excretion in benign adrenal tumors","volume":"175","author":"Prete","year":"2022","journal-title":"Ann Intern Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03492.x","article-title":"Hormonal activity of adrenal incidentalomas: results from a long-term follow-up study","volume":"70","author":"Vassilatou","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3275\/6377","article-title":"Prospective evaluation of tumor size and hormonal status in adrenal incidentalomas","volume":"33","author":"Yener","year":"2010","journal-title":"J Endocrinol Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab751","article-title":"Plasma steroid profiling in patients with adrenal incidentaloma","volume":"107","author":"Berke","year":"2022","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1179817\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T14:06:52Z","timestamp":1686060412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1179817\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":29,"alternative-id":["10.3389\/fendo.2023.1179817"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1179817","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"article-number":"1179817"}}